This invention is a hybrid intrastromal corneal ring (“ICR”) comprising at least one outer layer of a physiologically compatible polymer having a low modulus of elasticity, which polymer may be hydratable and may be hydrophilic. The inner portion of the ICR may be hollow or may contain one or more physiologically compatible polymers.
Anomalies in the overall shape of the eye can cause visual disorders. Hyperopia (“farsightedness”) occurs when the front-to-back distance in the eyeball is too short. In such a case, parallel rays originating greater than 20 feet from the eye focus behind the retina. In contrast, when the front-to-back distance of eyeball is too long, myopia (“nearsightedness”) occurs and the focus of parallel rays entering the eye occurs in front of the retina. Astigmatism is a condition which occurs when the parallel rays of light do not focus to a single point within the eye, but rather have a variable focus due to the fact that the cornea is aspherical and refracts light in a different meridian at different distances. Some degree of astigmatism is normal, but where it is pronounced, the astigmatism must be corrected.
Hyperopia, myopia, and astigmatism are usually corrected by glasses or contact lenses. Surgical methods for the correction of such disorders are known. Such methods include radial keratotomy (see, e.g., U.S. Pat. Nos. 4,815,463 and 4,688,570) and laser corneal ablation (see, e.g., U.S. Pat. No. 4,941,093).
Another method for correcting those disorders is through the implantation of polymeric rings in the eye's corneal stroma to change the curvature of the cornea. Previous work involving the implantation of polymethylmethacrylate (PMMA) rings, allograft corneal tissue, and hydrogels is well documented. One of the ring devices involves a split ring design which is inserted into a channel previously dissected in the stromal layer of the cornea. A minimally invasive incision is used both for producing the channel and for implanting the implant.
The use of ICRs made completely of certain hard, hydrophobic polymers is known. For instance, in the article “Intrastromal Implantation Eines Justierbaren Kunststofforings Zur Hornhautrefraktionsanderung,” Hartmann et al., Congress for German Society for Intraocular Lens Implantation, March 1989, pages 465–475, the use of intrastromal ring implants of rings of silicone, polymethylmethacrylate (“PMMA”), and fluorocarbons (“TEFLON”). Other disclosures of the use of PMMA in such intrastromal rings is found in U.S. Pat. No. 4,452,235 to Reynolds; U.S. Pat. No. 4,671,276 to Reynolds; U.S. Pat. No. 4,766,895 to Reynolds; and U.S. Pat. No. 4,961,744 to Kilmer et al. These documents do not suggest the use of multiple layers of differing materials in the ICRs.
The use of soft polymers as intrastromal inserts is not widely known. For instance, U.S. Pat. No. 5,090,955 to Simon, suggests an ICR which is made by introducing a settable polymer into an intrastromal channel which has been previously made and allowing the polymer to set. This procedure does not allow the surgeon to specify the size of the resulting ring nor is it a process which allows control of the flowing polymer within the eye.
Temirov et al, “Refractive circular tunnel keroplasty in the correction of high myopia”, Vestnik Oftalmologii 1991: 3-21-31, suggests the use of collagen thread as ICR material.
They specifically do not suggest the use of soft or hydrophilic polymers insertable into the cornea as ICRs.
This invention is a hybrid intrastromal corneal ring comprising at least one outer layer of a soft, low modulus, often hydrophilic, physiologically compatible polymer.
The portion of the ICR inside that outer layer may be hollow and adapted to be fillable with a biologic agent, drug or other liquid, emulsified, or time-release eye treatment material. The inner portion may comprise variously a core of a high modulus, physiologically compatible polymer or a further composite of a low modulus polymer or a high modulus polymer core or a high modulus polymer or a low modulus polymer core. The inner portion may comprise a polymeric material which is polymerized in situ after introduction into a hollow center layer.
The term “high modulus polymer” is meant to include physiologically compatible polymers such as PMMA; TEFLON; certain longer chain silicones; polycarbonate; and polyolefins such as polyethylene, polypropylene, polybutylene, their mixtures or other polyolefin interpolymers. The term “low modulus polymer” is meant to include physiologically compatible polymers and hydrogels, such as polyhydroxyethyl methacrylate (“polyHEMA”) or polyvinylpyrrolidone (“PVP”) or elastomeric materials and biologic polymers such as crosslinked dextran, hyaluronic acid, and heparin or the like. The low modulus hydratable polymers, in any case, may be of the type which is sufficiently cross-linked such that they do not swell upon contact with water (and subsequent hydration) or of the type which swells when hydrated. Additionally, the class of low modulus polymers is meant to include elastomeric polymers, e.g., latex rubber, colloids of polyester and polyether, polyurethanes, lower molecular weight silicones, isoprene, and the like, which are stable and physiologically compatible. Finally, the low modulus polymer may be a reinforced hydrogel such as an interpenetrating network of polymerized vinyl pyrrolidone and methyl methacrylate.
Our ICRs may be implanted into the stroma using a number of known techniques. If hydratable polymers are used, they may be hydrated before or after introduction into the intrastromal passageway created by the surgical device used to introduce these devices into the eye. If the outer layer is hydrated before insertion into the eye, the final size of the ring is set before that insertion. If the hydratable polymers are allowed to hydrate within the corneal space, the device (if appropriate polymers are chosen) will swell within the eye to its final size. If prehydrated, the outer layer often provides a measure of lubricity to the ICR, allowing it to be inserted with greater ease. Other of the noted low modulus polymers may also provide such lubricity.
This invention allows for adjustment of ICR thickness and diameter and provides a softer interface between a harder polymer core and corneal tissue.
Prior to explaining the details of the inventive devices, a short explanation of the physiology of the eye is needed to appreciate the functional relationship of the ICR to the eye.
The globe (10) of the eye consists of three concentric coverings enclosing the various transparent media through which the light must pass before reaching the light-sensitive retina (12). The outermost covering is a fibrous protective portion the posterior five-sixths of which is white and opaque and called the sclera (13), and sometimes referred to as the white of the eye where visible to the front. The anterior one-sixth of this outer layer is the transparent cornea (11).
A middle covering is mainly vascular and nutritive in function and is made up of the choroid, ciliary body (15), and iris (20). The choroid generally functions to maintain the retina (12). The ciliary body (15) is involved in suspending the lens (17) and accommodation of the lens. The iris (16) is the most anterior portion of the middle covering of the eye and is arranged in a frontal plane. It is a thin circular disc similar in function to the diaphragm of a camera, and is perforate near its center by a circular aperture called the pupil (20). The size of the pupil varies to regulate the amount of light which reaches the retina (12). It contracts also to accommodation, which serves to sharpen the focus by diminishing spherical aberration. The iris divides the space between the cornea (11) and the lens (17) into an anterior chamber (21) and posterior chamber. The innermost portion of covering is the retina (12), consisting of nerve elements which form the true receptive portion for visual impressions.
The retina (12) is a part of the brain arising as an outgrowth from the fore-brain, with the optic nerve (23) serving as a fiber tract connecting the retina part of the brain with the fore-brain. A layer of rods and cones, lying just beneath a pigmented epithelium on the anterior wall of the retina serve as visual cells or photoreceptors which transform physical energy (light) into nerve impulses.
The vitreous body (24) is a transparent gelatinous mass which fills the posterior four-fifths of the globe (10). At its sides it supports the ciliary body (15) and the retina (12). A frontal saucer-shaped depression houses the lens.
The lens (17) of the eye is a transparent bi-convex body of crystalline appearance placed between the iris (16) and vitreous body (24). Its axial diameter varies markedly with accommodation. A ciliary zonule (25), consisting of transparent fibers passing between the ciliary body (15) and lens (17) serves to hold the lens (17) in position and enables the ciliary muscle to act on it.
Referring again to the cornea (11), this outermost fibrous transparent coating resembles a watch glass. Its curvature is somewhat greater than the rest of the globe and is ideally spherical in nature. However, often it is more curved in one meridian than another giving rise to astigmatism. A central third of the cornea is called the optical zone with a slight flattening taking place outwardly thereof as the cornea thickens towards its periphery. Most of the refraction of the eye takes place through the cornea.
An anterior limiting lamella (33), referred to as Bowman's membrane or layer, is positioned between the epithelium (31) and the stroma (32) of the cornea. The stroma (32) is made up of lamellae having bands of fibrils parallel to each other and crossing the whole of the cornea. While most of the fibrous bands are parallel to the surface, some are oblique, especially anteriorly. A posterior limiting lamina (34) is referred to as Descemet's membrane. It is a strong membrane sharply defined from the stroma (32) and resistant to pathological processes of the cornea.
The endothelium (35) is the most posterior layer of the cornea and consists of a single layer of cells. The limbus (37) is the transition zone between the conjunctiva and sclera on the one hand and the cornea (11) on the other.
The inner portion or core (56) as shown in
The extent to which the outer layers swell upon hydration is dependent upon the type of polymer chosen and, when the polymer is hydratable, upon the amount of cross-linking found in the outer layers (54), and on the thickness of the layer. Generally speaking, the more highly linked the hydratable polymer, the smaller the amount of volume change upon hydration. Conversely, a polymer having only sufficient cross-linking for strength in the service in which this device is placed, will have a somewhat lower level of cross-linking. Alternatively, a substantially nonswellable polymer system may be formed of a hydrogel physically interpenetrated by another polymer which does not hydrate, e.g., polyHEMA. See, polyacylnitrite.
The thickness of the outer layer depends in large function upon the intended use of the ICR. For instance if the outer layer is to be used as a container for an inner volume of a settable polymer or drug, the outer layer may be relatively thicker. If the outer layer is used to provide a swellable outer layer which does not add significantly to the size of the ICR or is used functionally as a lubricant layer, the other layer may be quite thin even to the point of a layer of minimum coverage, perhaps as thin as a molecule thick.
The inventive device shown in
Alternatively, the ICR may be introduced into the intrastromal channel as the dissector is fully rotated in place, attached to the leading edge of the dissector, and pulled into the intrastromal channel as the dissector is rotated out of the eye.
The shell may be injected with a settable soft polymer core and allowed to expand to a desired thickness. Suitable injectable polymers are well known but include polyHEMA hydrogel, cross-linked collagen, cross-linked hyaluronic acid, siloxane gels, and organic-siloxane gels such as cross-linked methyl vinyl siloxane gels. The injected polymer sets after injection.
In the variation of the invention specified just above and shown in
The low modulus polymers used in this invention are often absorbent, particularly if they are hydratable, and may be infused with a drug or biologic agent which may be slowly released from the device after implantation of the ICR. For instance, the low modulus polymer may be loaded with a drug such as dexamethasone to reduce acute inflammatory response to implanting the device. This drug helps to prevent undesirable scarring or vascular ingrowth toward the ICR. Similarly, heparin, corticosteroids, antimitotics, antiinflammatories, and antiangiogenesis factors (such as nicotine adenine dinucleotide (NAD+)) may be included to reduce or prevent angiogenesis and inflammation.
Clearly, there are a variety of other drugs suitable for inclusion in the ICR. The choice will depend upon the use to which the drugs are put.
The terms and expressions which have been used in the description above are used only as terms of description and not of limitation. There is no intention of excluding equivalents of the features shown or described. It is recognized that one having ordinary skill in this art would perceive equivalence to the inventions claimed below, which equivalence would be within the spirit of the invention as expressed above.
This application is a continuation of U.S. Ser. No. 08/976,378, filed Nov. 21, 1997, now U.S. Pat. No. 6,096,076, which is a continuation of U.S. Ser. No. 08/579,451 filed Dec. 27, 1995, now abandoned, which is a divisional of U.S. Ser. No. 07/927,165 filed Aug. 7, 1992, now abandoned. The contents of these applications are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
1147568 | Thomson | Jul 1915 | A |
1981566 | Nigro | Nov 1934 | A |
2014995 | Washer | Sep 1935 | A |
2249906 | Longoria | Jul 1941 | A |
2473968 | Paton | Jun 1949 | A |
2754520 | Crawford, Jr. | Jul 1956 | A |
2818866 | Thomas | Jan 1958 | A |
3064643 | Dixon | Nov 1962 | A |
3074407 | Moon et al. | Jan 1963 | A |
3334629 | Cohn | Aug 1967 | A |
3656481 | Ness | Apr 1972 | A |
3729968 | Norris | May 1973 | A |
3948272 | Guibor | Apr 1976 | A |
4014335 | Arnold | Mar 1977 | A |
4026591 | Cleaveland | May 1977 | A |
4053953 | Flom et al. | Oct 1977 | A |
4061146 | Baehr et al. | Dec 1977 | A |
4127112 | Sherlock et al. | Nov 1978 | A |
4139575 | Amann et al. | Feb 1979 | A |
4205682 | Crock et al. | Jun 1980 | A |
4298004 | Schachar et al. | Nov 1981 | A |
4316292 | Alexeev | Feb 1982 | A |
4319575 | Bonte | Mar 1982 | A |
4332039 | La Fuente | Jun 1982 | A |
4345601 | Fukuda | Aug 1982 | A |
4346482 | Tennant et al. | Aug 1982 | A |
4346713 | Malmin | Aug 1982 | A |
4357941 | Golubkov et al. | Nov 1982 | A |
4382444 | Malmin | May 1983 | A |
4417579 | Soloviev et al. | Nov 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4428746 | Mendez | Jan 1984 | A |
4429696 | Hanna | Feb 1984 | A |
4439196 | Higuchi | Mar 1984 | A |
4452235 | Reynolds | Jun 1984 | A |
4455143 | Theeuwes et al. | Jun 1984 | A |
4457757 | Molteno | Jul 1984 | A |
4466705 | Michelson | Aug 1984 | A |
4512338 | Balko et al. | Apr 1985 | A |
4549529 | White | Oct 1985 | A |
4565198 | Koeniger | Jan 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4614187 | Mulhollan et al. | Sep 1986 | A |
4619259 | Graybill et al. | Oct 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4646720 | Peyman et al. | Mar 1987 | A |
4647282 | Fedorov et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4662370 | Hoffmann et al. | May 1987 | A |
4671276 | Reynolds | Jun 1987 | A |
4673376 | Fender | Jun 1987 | A |
4682597 | Myers | Jul 1987 | A |
4688570 | Kramer et al. | Aug 1987 | A |
4693939 | Ofstead | Sep 1987 | A |
4705035 | Givens | Nov 1987 | A |
4706996 | Fasham | Nov 1987 | A |
4709996 | Michelson | Dec 1987 | A |
4731080 | Galin | Mar 1988 | A |
4739761 | Grandon | Apr 1988 | A |
4739768 | Engelson | Apr 1988 | A |
4766895 | Reynolds | Aug 1988 | A |
4773415 | Tan | Sep 1988 | A |
4781187 | Herrick | Nov 1988 | A |
4782820 | Woods | Nov 1988 | A |
4787885 | Binder | Nov 1988 | A |
4799931 | Lindstrom | Jan 1989 | A |
4813934 | Engelson et al. | Mar 1989 | A |
4815463 | Hanna | Mar 1989 | A |
4819617 | Goldberg et al. | Apr 1989 | A |
4828563 | Müller-Lierheim | May 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4884579 | Engelson | Dec 1989 | A |
4901744 | Hansen | Feb 1990 | A |
4907587 | Fedorov et al. | Mar 1990 | A |
4941093 | Marshall et al. | Jul 1990 | A |
4957501 | Lahille et al. | Sep 1990 | A |
4961744 | Kilmer et al. | Oct 1990 | A |
4976719 | Siepser | Dec 1990 | A |
4983181 | Civerchia | Jan 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
4994081 | Civerchia et al. | Feb 1991 | A |
5037427 | Harada et al. | Aug 1991 | A |
5066301 | Wiley | Nov 1991 | A |
5067961 | Kelman et al. | Nov 1991 | A |
5090955 | Simon | Feb 1992 | A |
5094876 | Goldberg et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5108407 | Geremia et al. | Apr 1992 | A |
5109867 | Twyford, Jr. | May 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5123921 | Werblin et al. | Jun 1992 | A |
5188125 | Kilmer et al. | Feb 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5300114 | Gwon et al. | Apr 1994 | A |
5300118 | Silvestrini et al. | Apr 1994 | A |
5312424 | Kilmer et al. | May 1994 | A |
5318047 | Davenport et al. | Jun 1994 | A |
5323788 | Silvestrini et al. | Jun 1994 | A |
5354331 | Schachar | Oct 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5391201 | Barrett et al. | Feb 1995 | A |
5403335 | Loomas et al. | Apr 1995 | A |
5405384 | Silvestrini | Apr 1995 | A |
5452235 | Isani | Sep 1995 | A |
5466260 | Silvestrini et al. | Nov 1995 | A |
5475452 | Kuhn et al. | Dec 1995 | A |
5505722 | Kilmer et al. | Apr 1996 | A |
5592246 | Kuhn et al. | Jan 1997 | A |
5645582 | Silvestrini et al. | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5693092 | Silvestrini et al. | Dec 1997 | A |
5766171 | Silvestrini | Jun 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
RE35974 | Davenport et al. | Dec 1998 | E |
5843105 | Mathis et al. | Dec 1998 | A |
5846256 | Mathis et al. | Dec 1998 | A |
5876439 | Lee | Mar 1999 | A |
5888243 | Silverstrini | Mar 1999 | A |
5919228 | Hennig | Jul 1999 | A |
5946526 | Kim | Aug 1999 | A |
Number | Date | Country |
---|---|---|
8 705 060 | Mar 1989 | BR |
0 295 962 | May 1916 | DE |
2 719 688 | May 1978 | DE |
3 208 729 | Sep 1983 | DE |
3 620 148 | Mar 1987 | DE |
0 205 997 | Dec 1986 | EP |
0 212 616 | Mar 1987 | EP |
0 420 549 | Apr 1991 | EP |
0 557 128 | Aug 1993 | EP |
0 660 732 | Jul 1995 | EP |
1 125 621 | Nov 1956 | FR |
1 366 323 | Jun 1964 | FR |
1 383 768 | Jan 1965 | FR |
2 053 398 | Apr 1971 | FR |
2 354 752 | Jan 1978 | FR |
2 487 667 | Feb 1982 | FR |
2 601 872 | Jan 1988 | FR |
2 608 041 | Jun 1988 | FR |
637 640 | May 1950 | GB |
1 006 102 | Sep 1965 | GB |
2 029 235 | Mar 1980 | GB |
1 601 334 | Oct 1981 | GB |
2 095 119 | Dec 1981 | GB |
2 250 442 | Jun 1992 | GB |
58-212828 | Dec 1983 | JP |
303 061 | May 1971 | RU |
388 746 | Jul 1973 | RU |
1 597 188 | Oct 1990 | RU |
1 771 730 | Oct 1992 | RU |
WO 8503217 | Aug 1985 | WO |
WO 8810096 | Dec 1988 | WO |
WO 8904153 | May 1989 | WO |
WO 9117789 | Nov 1991 | WO |
WO 9200112 | Jan 1992 | WO |
WO 9313724 | Jul 1993 | WO |
WO 9403129 | Feb 1994 | WO |
WO 9405232 | Mar 1994 | WO |
WO 9406504 | Mar 1994 | WO |
WO 9517144 | Jun 1995 | WO |
WO 9728759 | Aug 1997 | WO |
Number | Date | Country | |
---|---|---|---|
Parent | 07927165 | Aug 1992 | US |
Child | 08579451 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 08976378 | Nov 1997 | US |
Child | 09281623 | US | |
Parent | 08579451 | Dec 1995 | US |
Child | 08976378 | US |